Monroe Capital has appointed Matthew Evans to the firm’s healthcare team as managing director in its Chicago office. Prior to Monroe, Matt was a principal at Beverly Capital, a healthcare focused private equity firm.
Monroe Capital LLC today announced Matthew Evans has joined the firm’s healthcare team as Managing Director in its Chicago office.
“We are very excited to add Matt to the Monroe Capital team,” said Ted Koenig, President & CEO of Monroe Capital. “Matt has had an extensive financial career working with middle market companies across the healthcare industry. Matt will be responsible for leading our healthcare lending efforts in addition to originating cash flow and enterprise value based loans in private equity sponsored and non-sponsored transactions.”
Prior to Monroe, Matt was a Principal at Beverly Capital, a healthcare focused private equity firm. He was formerly a Vice President in the Healthcare Leveraged Finance group at Madison Capital where he originated, structured and underwrote debt financing for private equity sponsored transactions. Prior to Madison Capital, Mr. Evans worked in Merrill Lynch Capital’s Healthcare Finance leveraged lending group.
About Monroe Capital
Monroe Capital LLC is a leading provider of senior and junior debt and equity co-investments to middle-market companies in the U.S. and Canada. Investment types include unitranche financings, cash flow and enterprise value based loans, acquisition facilities, mezzanine debt, second lien or last-out loans and equity co-investments. Monroe Capital prides itself on its flexible investment approach and its ability to close and fund transactions quickly. Monroe is committed to being a value-added and user-friendly partner to owners, senior management and private equity sponsors. To learn more about Monroe Capital LLC, visit www.monroecap.com.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.